HEIDELBERG, GERMANY and CAMBRIDGE, UNITED KINGDOM--(MARKET WIRE)--Aug 27, 2007 -- An article published in Nature Biotechnology today describes how Cellzome scientists, using a new technology called Kinobeads(TM), have assessed the molecular action of two approved Chronic Myeloid Leukemia (CML) drugs - Gleevec® and Sprycel® and one which is currently undergoing clinical testing, SKI-606. The team discovered novel targets for all three drugs, including two new targets for Gleevec, suggesting a potential new disease indication for the billion $ cancer drug.
